Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.52 |
| ▸ | GPR183 | P32249 | 3/20 | 0.52 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26490234 | 0.89 | HRH4 (0.68) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL5772882 | 0.86 | HRH4 (0.74) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL20267020 | 0.82 | MEN1 (0.65) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL26490547 | 0.82 | HRH4 (0.70) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL377743 | 0.82 | HRH4 (0.78) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL604107 | 0.81 | HRH4 (1.00) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL21225832 | 0.80 | HRH4 (0.62) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL21224920 | 0.80 | HRH4 (0.62) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL25531368 | 0.79 | HRH4 (0.62) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL1612954 | 0.78 | HRH3 (0.72) | MEN1KMT2APOLBHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787783-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | MEN1 3249/4885KMT2A 3905/4885POLB 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.